Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00085189 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
A Phase 2 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00085189: Completed Phase 2 study, sponsored by University of Southern California.
NCT00085189 is a Phase 2 study that has completed, run by University of Southern California. The registered enrollment target is 42 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00085189, a Phase 2 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
This pilot phase II trial studies how well giving vaccine therapy works in treating patients with stage IIC-IV melanoma. Vaccines made from melanoma peptides or antigens may help the body build an effective immune response to kill tumor cells
Interventions
- BIOLOGICAL incomplete Freund's adjuvant
- BIOLOGICAL gp100 antigen
- BIOLOGICAL multi-epitope melanoma peptide vaccine
- BIOLOGICAL tyrosinase peptide
- BIOLOGICAL recombinant MAGE-3.1 antigen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2004-05 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
What the finished NCT00085189 record still lists
NCT00085189 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 5 interventions - of which incomplete Freund's adjuvant is the first listed.
NCT00085189 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00085189 about?
NCT00085189 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma". This pilot phase II trial studies how well giving vaccine therapy works in treating patients with stage IIC-IV melanoma. Vaccines made from melanoma peptides or antigens may help the body build an effective immune response to kill tumor cells
What is the current status of trial NCT00085189?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2004-05. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00085189?
The interventions under investigation include: incomplete Freund's adjuvant (BIOLOGICAL), gp100 antigen (BIOLOGICAL), multi-epitope melanoma peptide vaccine (BIOLOGICAL), tyrosinase peptide (BIOLOGICAL), recombinant MAGE-3.1 antigen (BIOLOGICAL).
Who is sponsoring clinical trial NCT00085189?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00085189's enrollment target sits among peer trials
42 1339th of 2000 higher than 649 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia